Lung cancer combo trial halted early – what we learned
NCT ID NCT03307759
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 31 times
Summary
This early-stage trial looked at the safety of giving radiation therapy either before or after an immunotherapy drug (pembrolizumab) in 13 people with advanced non-small cell lung cancer. The goal was to find the best sequence to control the disease. The study was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peter MacCallum Cancer Centre
Melbourne, Victoria, 3000, Australia
Conditions
Explore the condition pages connected to this study.